Gensenoside Rg3 inhibits hypoxia-induced VEGF expression in human cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Ginsenoside Rg3 (Rg3) demonstrates anti-tumor properties by inhibiting xenograft growth and angiogenesis.
• The primary mechanism involves the downregulation of vascular endothelial growth factor (VEGF) expression.

Purpose of the Study:

• To elucidate the specific mechanisms by which Rg3 downregulates VEGF expression.
• To investigate Rg3's effects on cancer cell proliferation and key signaling pathways under varying oxygen conditions.

Main Methods:

• MTT assays were used to assess Rg3's impact on Eca-109 and 786-0 cell proliferation under normoxia and hypoxia.
• ELISA, real-time quantitative reverse transcriptase polymerase chain reaction, and Western blotting were employed to measure VEGF protein and gene expression, as well as protein synthesis.

Main Results:

• Rg3 inhibited proliferation and reduced VEGF mRNA in esophageal carcinoma cells under hypoxia.
• Rg3 suppressed hypoxia-induced expression of HIF-1α, COX-2, and NF-κB.
• Rg3 dose-dependently inhibited hypoxia-induced phosphorylation of STAT3, ERK1/2, and JNK.

Conclusions:

• Rg3 downregulates VEGF expression by targeting multiple hypoxia-induced signaling pathways in cancer cells.
• These molecular actions likely contribute to Rg3's effectiveness in combating tumor angiogenesis and growth.